Table of Contents for U.S. Market for Gastrointestinal Pharmaceuticals
|
INTRODUCTION |
XIX |
|
STUDY GOALS AND OBJECTIVES |
XIX |
|
REASONS FOR DOING THE STUDY |
XIX |
|
CONTRIBUTIONS OF THE STUDY AND FOR WHOM |
XIX |
|
SCOPE AND FORMAT |
XX |
|
METHODOLOGY AND INFORMATION SOURCES |
XX |
|
ANALYST CREDENTIALS |
XXI |
|
RELATED BCC REPORTS |
XXI |
|
BCC ONLINE SERVICES |
XXII |
|
DISCLAIMER |
XXII |
|
EXECUTIVE SUMMARY |
XXIII |
|
Summary Table: |
XXIV |
|
Summary Figure: |
XXIV |
|
INDUSTRY OVERVIEW |
1 |
|
STRUCTURE AND FUNCTION OF THE GASTROINTESTINAL SYSTEM |
1 |
|
INGESTION AND PROPULSION OF FOOD |
2 |
|
Mouth |
3 |
|
Pharynx |
3 |
|
Esophagus |
3 |
|
DIGESTION AND ABSORPTION |
4 |
|
Mouth |
4 |
|
Stomach |
4 |
|
Small Intestines |
5 |
|
Physiology of Digestion |
5 |
|
ELIMINATION |
6 |
|
Large Intestine |
6 |
|
Large Intestine (Continued) |
7 |
|
LIVER, BILIARY TRACT AND PANCREAS |
8 |
|
LIVER |
8 |
|
BILARY TRACT |
8 |
|
Bilirubin Metabolism |
9 |
|
PANCREAS |
9 |
|
GASTROINTESTINAL TRACT DISORDERS |
9 |
|
DYSPHAGIA |
9 |
|
Dysphagia (Continued) |
10 |
|
ESOPHAGEAL AND ABDOMINAL PAIN |
11 |
|
VOMITING |
12 |
|
INTESTINAL GAS |
12 |
|
CONSTIPATION |
13 |
|
DIARRHEA |
13 |
|
Table 1 CAUSES OF DIARRHEA |
13 |
|
Table 1 (CONTINUED) |
14 |
|
GASTROINTESTINAL TRACT WALL DISORDERS |
14 |
|
GASTRITIS |
14 |
|
Table 2 COMMON CAUSES OF GASTRITIS |
15 |
|
GASTROENTERITIS |
16 |
|
PEPTIC ULCER DISEASE |
17 |
|
Peptic Ulcer Disease (Continued) |
18 |
|
GASTRIC ULCERS |
19 |
|
DUODENAL ULCERS |
20 |
|
INFLAMMATORY BOWEL DISEASE |
21 |
|
ULCERATIVE COLITIS |
21 |
|
CROHN'S DISEASE |
22 |
|
ENTEROCOLITIS |
23 |
|
DIVERTICULAR DISEASE |
23 |
|
GASTROINTESTINAL TRACT MOTILITY DISORDERS |
24 |
|
IRRITABLE BOWEL SYNDROME |
24 |
|
INTESTINAL OBSTRUCTION |
24 |
|
GASTROINTESTINAL MALABSORPTION DISORDERS |
25 |
|
CELIAC DISEASE |
26 |
|
TROPICAL SPRUE |
26 |
|
CANCERS OF THE GASTROINTESTINAL TRACT |
27 |
|
ESOPHAGEAL CANCER |
27 |
|
GASTRIC CANCER |
27 |
|
Gastric Cancer (Continued) |
28 |
|
LIVER CANCER |
29 |
|
PANCREATIC CANCER |
29 |
|
SMALL INTESTINAL CANCER |
30 |
|
COLONIC POLYPS AND COLON CANCER |
31 |
|
DEMOGRAPHICS |
32 |
|
Table 3 U.S. ESTIMATED INCIDENCE/PREVALENCE/MORTALITY OF SELECTED GASTROINTESTINAL CONDITIONS |
32 |
|
Table 4 U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, 2002-2030 (THOUSANDS) |
33 |
|
Figure 1 U.S. POPULATION BY SELECTED AGE GROUPS, 2002-2030 (THOUSANDS) |
34 |
|
Figure 2 U.S. POPULATION SELECTED AGE GROUPS BY PERCENT OF TOTAL POPULATION, 2002-2030 (%) |
34 |
|
PILL-SIZED VIDEO CAMERA |
35 |
|
INSURANCE COVERAGE |
35 |
|
USE OF CELEBREX FOR ULCERATIVE COLITIS |
36 |
|
FAST-ACTING ACID PUMP ANTAGONISTS |
36 |
|
RADIO FREQUENCY IDENTIFICATION TECHNOLOGY |
37 |
|
BRANDED VS OTC PROTON PUMP INHIBITORS |
37 |
|
PHARMACEUTICAL AND HEALTH CARE COSTS |
38 |
|
Pharmaceutical and Health Care Costs (Continued) |
39 |
|
Table 5 PATENT EXPIRATION FOR SELECTED PRESCRIPTION GASTROINTESTINAL DRUGS 2005-2013 |
40 |
|
MAIL ORDER TRENDS |
41 |
|
Mail Order Trends (Continued) |
42 |
|
PRESCRIPTION PRODUCT SEGMENTS BY TYPE |
43 |
|
ANTIDIARRHEALS |
43 |
|
SYSTEMICALLY ACTING ANTIDIARRHEALS |
44 |
|
OPIUM PRODUCTS |
44 |
|
Table 6 MARKETED ANTIDIARRHEAL PRODUCTS |
45 |
|
MARKET SIZE AND GROWTH |
45 |
|
Table 7 PRODUCT REVENUES OF U.S. PRESCRIPTION ANTIDIARRHEALS AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 ($ MILLIONS) |
46 |
|
Figure 3 PRODUCT REVENUES OF U.S. PRESCRIPTION ANTIDIARRHEALS AT U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 ($ MILLIONS) |
46 |
|
COMPETITIVE STRUCTURE AND MARKET SHARE |
46 |
|
Table 8 U.S. PRESCRIPTION ANTIDIARRHEALS MANUFACTURERS' REVENUES AND MARKET SHARE, 2004 ($ MILLIONS, %) |
47 |
|
Figure 4 U.S. PRESCRIPTION ANTIDIARRHEALS MANUFACTURERS' MARKET SHARE, 2004 (%) |
47 |
|
ANTIEMETICS |
47 |
|
LOCALLY ACTING ANTIEMETICS |
48 |
|
CENTRALLY ACTING ANTIEMETICS |
48 |
|
ANTIDOPAMINERGICS |
48 |
|
Antidopaminergics (Continued) |
49 |
|
ANTICHOLINERGICS |
50 |
|
MISCELLANEOUS ANTIEMETICS |
50 |
|
Miscellaneous Antiemetics (Continued) |
51 |
|
Table 9 MARKETED ANTIEMETIC PRODUCTS |
52 |
|
MARKET SIZE AND GROWTH |
52 |
|
Table 10 PRODUCT REVENUES OF U.S. PRESCRIPTION ANTIEMETICS AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 ($ MILLIONS) |
53 |
|
Figure 5 PRODUCT REVENUES OF U.S. PRESCRIPTION ANTIEMETICS AT U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 ($ MILLIONS) |
53 |
|
COMPETITIVE STRUCTURE AND MARKET SHARE |
53 |
|
Table 11 U.S. PRESCRIPTION ANTIEMETIC MANUFACTURERS' REVENUES AND MARKET SHARE, 2004 ($ MILLIONS, %) |
54 |
|
Figure 6 U.S. PRESCRIPTION ANTIEMETICS MANUFACTURERS' MARKET SHARE, 2004 (%) |
54 |
|
GASTROINTESTINAL CANCER TREATMENTS |
55 |
|
GASTROINTESTINAL CANCER…(CONTINUED) |
56 |
|
Table 12 MARKETED GASTROINTESTINAL CANCER PRODUCTS |
57 |
|
MARKET SIZE AND GROWTH |
57 |
|
Table 13 PRODUCT REVENUES OF U.S. PRESCRIPTION GASTROINTESTINAL CANCER DRUGS AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 ($ MILLIONS) |
58 |
|
Figure 7 PRODUCT REVENUES OF U.S. PRESCRIPTION GASTROINTESTINAL CANCER DRUGS AT U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 ($ MILLIONS) |
58 |
|
COMPETITIVE STRUCTURE AND MARKET SHARE |
58 |
|
Table 14 U.S. PRESCRIPTION GASTROINTESTINAL CANCER DRUGS MANUFACTURERS' REVENUES AND MARKET SHARE, 2004 ($ MILLIONS, %) |
59 |
|
Figure 8 U.S. PRESCRIPTION GASTROINTESTINAL CANCER DRUGS MANUFACTURERS' MARKET SHARE, 2004 (%) |
59 |
|
H2 INHIBITORS |
60 |
|
H2 INHIBITORS (CONTINUED) |
61 |
|
H2 INHIBITORS (CONTINUED) |
62 |
|
Table 15 MARKETED H2 INHIBITORS PRODUCTS |
63 |
|
MARKET SIZE AND GROWTH |
63 |
|
Table 16 PRODUCT REVENUES OF U.S. PRESCRIPTION H2 INHIBITORS AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 ($ MILLIONS) |
63 |
|
Figure 9 PRODUCT REVENUES OF U.S. PRESCRIPTION H2 INHIBITORS AT U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 ($ MILLIONS) |
64 |
|
COMPETITIVE STRUCTURE AND MARKET SHARE |
64 |
|
Table 17 U.S. PRESCRIPTION H2 INHIBITORS MANUFACTURERS' REVENUES AND MARKET SHARE, 2004 ($ MILLIONS, %) |
64 |
|
Figure 10 U.S. PRESCRIPTION H2 INHIBITORS MANUFACTURERS' MARKET SHARE, 2004 (%) |
65 |
|
LAXATIVES |
65 |
|
Table 18 MARKETED LAXATIVE PRODUCTS |
66 |
|
MARKET SIZE AND GROWTH |
67 |
|
Table 19 PRODUCT REVENUES OF U.S. PRESCRIPTION LAXATIVES AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 ($ MILLIONS) |
67 |
|
Figure 11 PRODUCT REVENUES OF U.S. PRESCRIPTION LAXATIVES AT U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 ($ MILLIONS) |
67 |
|
COMPETITIVE STRUCTURE AND MARKET SHARE |
68 |
|
Table 20 U.S. PRESCRIPTION LAXATIVES MANUFACTURERS' REVENUES AND MARKET SHARE, 2004 ($ MILLIONS, %) |
68 |
|
Figure 12 U.S. PRESCRIPTION LAXATIVES MANUFACTURERS' MARKET SHARE, 2004 (%) |
68 |
|
PROTON PUMP INHIBITORS |
69 |
|
PROTON PUMP INHIBITORS (CONTINUED) |
70 |
|
Table 21 MARKETED PROTON PUMP INHIBITOR PRODUCTS |
71 |
|
MARKET SIZE AND GROWTH |
71 |
|
Table 22 PRODUCT REVENUES OF U.S. PRESCRIPTION PROTON PUMP INHIBITORS AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 ($ MILLIONS) |
72 |
|
Figure 13 PRODUCT REVENUES OF U.S. PRESCRIPTION PROTON PUMP INHIBITORS AT U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 ($ MILLIONS) |
72 |
|
COMPETITIVE STRUCTURE AND MARKET SHARE |
72 |
|
Table 23 U.S. PRESCRIPTION PROTON PUMP INHIBITORS MANUFACTURERS' REVENUES AND MARKET SHARE, 2004 ($ MILLIONS, %) |
73 |
|
Figure 14 U.S. PRESCRIPTION PROTON PUMP INHIBITORS MANUFACTURERS' MARKET SHARE, 2004 (%) |
73 |
|
ANTI-INFLAMMATORY |
74 |
|
Table 24 MARKETED INFLAMMATORY PRODUCTS |
74 |
|
MARKET SIZE AND GROWTH |
75 |
|
Table 25 PRODUCT REVENUES OF U.S. PRESCRIPTION GASTROINTESTINAL INFLAMMATORY AGENTS AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 ($ MILLIONS) |
75 |
|
Figure 15 PRODUCT REVENUES OF U.S. PRESCRIPTION GASTROINTESTINAL INFLAMMATORY AGENTS AT U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 ($ MILLIONS) |
75 |
|
COMPETITIVE STRUCTURE AND MARKET SHARE |
76 |
|
Table 26 U.S. PRESCRIPTION GASTROINTESTINAL INFLAMMATORY AGENTS MANUFACTURERS' REVENUES AND MARKET SHARE, 2004 ($ MILLIONS, %) |
76 |
|
Figure 16 U.S. PRESCRIPTION GASTROINTESTINAL INFLAMMATORY AGENTS MANUFACTURERS' MARKET SHARE, 2004 (%) |
76 |
|
OTHER GASTROINTESTINAL PRODUCTS |
77 |
|
ANTISPASMODICS |
77 |
|
Table 27 MARKETED ANTISPASMODIC PRODUCTS |
77 |
|
DIGESTANTS |
77 |
|
GASTRIC ACIDIFIERS |
78 |
|
PANCREATIC ENZYMES |
78 |
|
Table 28 MARKETED DIGESTANT PRODUCTS |
78 |
|
EVACUANTS |
79 |
|
Table 29 MARKETED EVACUANTS PRODUCTS |
79 |
|
MUCOSAL PROTECTANTS |
79 |
|
Table 30 MARKETED MUCOSAL PROTECTANT PRODUCTS |
80 |
|
PROSTAGLANDINS |
80 |
|
Table 31 MARKETED PROSTAGLANDIN PRODUCTS |
80 |
|
STIMULANTS |
81 |
|
Table 32 MARKETED STIMULANT PRODUCTS |
81 |
|
MARKET SIZE AND GROWTH |
81 |
|
Table 33 PRODUCT REVENUES OF U.S. PRESCRIPTION OTHER GASTROINTESTINAL DRUGS AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 ($ MILLIONS) |
82 |
|
Figure 17 PRODUCT REVENUES OF U.S. PRESCRIPTION OTHER GASTROINTESTINAL DRUGS AT U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 ($ MILLIONS) |
82 |
|
COMPETITIVE STRUCTURE AND MARKET SHARE |
82 |
|
Table 34 U.S. PRESCRIPTION OTHER GASTROINTESTINAL DRUG MANUFACTURERS' REVENUES AND MARKET SHARE, 2004 ($ MILLIONS, %) |
83 |
|
Figure 18 U.S. PRESCRIPTION OTHER GASTROINTESTINAL DRUG MANUFACTURERS' MARKET SHARE, 2004 (%) |
83 |
|
TOTAL U.S. PRESCRIPTION GASTROINTESTINAL MARKET SIZE AND GROWTH |
84 |
|
Table 35 MARKET SIZE OF U.S. PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT MARKETS BY TYPE AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 ($ MILLIONS) |
84 |
|
Figure 19 MARKET SIZE OF U.S. PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT MARKET BY TYPE AT U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 ($ MILLIONS) |
85 |
|
TOTAL U.S. PRESCRIPTION GASTROINTESTINAL COMPETITIVE ANALYSIS |
85 |
|
Table 36 TOTAL MANUFACTURERS SALES AND MARKET SHARE OF PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENTS AT U.S. MANUFACTURERS' SALES LEVELS, 2004 ($ MILLIONS) |
86 |
|
Figure 20 MANUFACTURERS MARKET SHARE OF TOTAL PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENTS AT U.S. MANUFACTURERS' SALES LEVELS, 2004 (%) |
87 |
|
OTC PRODUCT SEGMENTS BY TYPE |
88 |
|
ANTACIDS |
88 |
|
SYSTEMIC ANTACIDS |
89 |
|
Sodium Bicarbonate |
89 |
|
NONSYSTEMIC ANTACIDS |
89 |
|
Calcium Carbonate |
89 |
|
Aluminum Products |
90 |
|
Magnesium Products |
90 |
|
Combination Products |
91 |
|
Table 37 MARKETED OTC ANTACID PRODUCTS |
91 |
|
Table 37 (CONTINUED) |
92 |
|
MARKET SIZE AND GROWTH |
92 |
|
Table 38 PRODUCT REVENUES OF U.S. OTC ANTACIDS AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 ($ MILLIONS) |
92 |
|
Figure 21 PRODUCT REVENUES OF U.S. OTC ANTACIDS AT U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 ($ MILLIONS) |
93 |
|
COMPETITIVE STRUCTURE AND MARKET SHARE |
93 |
|
Table 39 U.S. OTC ANTACID MANUFACTURERS' REVENUES AND MARKET SHARE, 2004 ($ MILLIONS, %) |
94 |
|
Figure 22 U.S. OTC ANTACID MANUFACTURERS' MARKET SHARE, 2004 (%) |
94 |
|
LOCALLY ACTING ANTIDIARRHEALS |
94 |
|
ADSORBENTS |
95 |
|
INTESTINAL FLORA MODIFIERS |
96 |
|
Table 40 MARKETED OTC ANTIDIARRHEAL PRODUCTS |
96 |
|
MARKET SIZE AND GROWTH |
96 |
|
Table 41 PRODUCT REVENUES OF U.S. OTC ANTIDIARRHEALS AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 ($ MILLIONS) |
97 |
|
Figure 23 PRODUCT REVENUES OF U.S. OTC ANTIDIARRHEALS AT U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 ($ MILLIONS) |
97 |
|
COMPETITIVE STRUCTURE AND MARKET SHARE |
97 |
|
Table 42 U.S. OTC ANTIDIARRHEALS MANUFACTURERS' REVENUES AND MARKET SHARE, 2004 ($ MILLIONS, %) |
98 |
|
Figure 24 U.S. OTC ANTIDIARRHEALS MANUFACTURERS' MARKET SHARE, 2004 (%) |
98 |
|
H2 INHIBITORS |
99 |
|
H2 INHIBITORS (CONTINUED) |
100 |
|
H2 INHIBITORS (CONTINUED) |
101 |
|
Table 43 MARKETED OTC H2 INHIBITORS PRODUCTS |
102 |
|
MARKET SIZE AND GROWTH |
102 |
|
Table 44 PRODUCT REVENUES OF U.S. OTC H2 INHIBITORS AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 ($ MILLIONS) |
102 |
|
Figure 25 PRODUCT REVENUES OF U.S. OTC H2 INHIBITORS AT U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 ($ MILLIONS) |
103 |
|
COMPETITIVE STRUCTURE AND MARKET SHARE |
103 |
|
Table 45 U.S. OTC H2 INHIBITOR MANUFACTURERS' REVENUES AND MARKET SHARE, 2004 ($ MILLIONS, %) |
104 |
|
Figure 26 U.S. OTC H2 INHIBITOR MANUFACTURERS' MARKET SHARE, 2004 (%) |
104 |
|
PROTON PUMP INHIBITORS |
104 |
|
OMEPRAZOLE (PRILOSEC, PROCTOR & GAMBLE) |
104 |
|
Table 46 MARKETED OTC PROTON PUMP INHIBITOR PRODUCTS |
105 |
|
MARKET SIZE AND GROWTH |
105 |
|
Table 47 PRODUCT REVENUES OF U.S. OTC PROTON PUMP INHIBITORS AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 ($ MILLIONS) |
106 |
|
Figure 27 PRODUCT REVENUES OF U.S. OTC PROTON PUMP INHIBITORS AT U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 ($ MILLIONS) |
106 |
|
COMPETITIVE STRUCTURE AND MARKET SHARE |
106 |
|
Table 48 U.S. OTC PROTON PUMP INHIBITOR MANUFACTURERS' REVENUES AND MARKET SHARE, 2004 ($ MILLIONS, %) |
107 |
|
OTHER OTC GASTROINTESTINAL PRODUCTS |
107 |
|
ANTIEMETICS |
107 |
|
Locally Acting Antiemetics |
107 |
|
Centrally Acting Antiemetics |
108 |
|
Table 49 MARKETED OTC ANTIEMETICS PRODUCTS |
108 |
|
EMETICS |
108 |
|
Table 50 MARKETED OTC EMETIC PRODUCTS |
109 |
|
ANTIFLATULENCE PRODUCTS |
109 |
|
Table 51 MARKETED OTC ANTIFLATULENCE PRODUCTS |
109 |
|
Table 51 (CONTINUED) |
110 |
|
LAXATIVES |
110 |
|
Table 52 MARKETED OTC LAXATIVE PRODUCTS |
111 |
|
MARKET SIZE AND GROWTH |
111 |
|
Table 53 PRODUCT REVENUES OF U.S. OTC OTHER GASTROINTESTINAL DRUGS AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 ($ MILLIONS) |
111 |
|
Figure 28 PRODUCT REVENUES OF U.S. OTC OTHER GASTROINTESTINAL DRUGS AT U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 ($ MILLIONS) |
112 |
|
COMPETITIVE STRUCTURE AND MARKET SHARE |
112 |
|
Table 54 U.S. OTC OTHER GASTROINTESTINAL DRUGS MANUFACTURERS' REVENUES AND MARKET SHARE, 2004 ($ MILLIONS, %) |
112 |
|
Figure 29 U.S. OTC OTHER GASTROINTESTINAL DRUGS MANUFACTURERS' MARKET SHARE, 2004 (%) |
113 |
|
TOTAL U.S. OTC GASTROINTESTINAL DRUG MARKET SIZE AND GROWTH |
113 |
|
Table 55 MARKET SIZE OF U.S. GASTROINTESTINAL DISORDER TREATMENT MARKET BY TYPE AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 ($ MILLIONS) |
113 |
|
Figure 30 MARKET SIZE OF U.S. GASTROINTESTINAL DISORDER TREATMENT MARKET BY TYPE AT U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 ($ MILLIONS) |
114 |
|
TOTAL U.S. OTC GASTROINTESTINAL DRUG COMPETITIVE ANALYSIS |
114 |
|
Table 56 MANUFACTURERS MARKET SHARE OF TOTAL OTC GASTROINTESTINAL DISORDER TREATMENTS AT U.S. MANUFACTURERS' SALES LEVELS, 2004 ($ MILLIONS, %) |
115 |
|
Figure 31 TOTAL MANUFACTURERS MARKET SHARE OF OTC GASTROINTESTINAL DISORDER TREATMENTS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, 2004 (%) |
115 |
|
RESEARCH AND DEVELOPMENT |
116 |
|
CALMACTIN |
116 |
|
CANASA |
116 |
|
ENTEREG |
116 |
|
PTK787 |
117 |
|
RAPINEX |
117 |
|
TYSABRI |
117 |
|
ALICAFORSEN |
118 |
|
CDP-870 |
118 |
|
CDP-870 (Continued) |
119 |
|
METHYLNALTREXONE (MNTX) |
120 |
|
OPC-6535 |
120 |
|
ORBEC |
120 |
|
SUCAMPO |
121 |
|
RENZAPRIDE |
121 |
|
683699 |
121 |
|
ABT-224 |
122 |
|
ALICAFORSEN ENEMA |
122 |
|
DEXTOFISOPAM |
122 |
|
EKB-569 |
122 |
|
GTI-2040 |
122 |
|
PUMOSETRAG |
123 |
|
RDP-58 |
123 |
|
SORAPRAZAN |
123 |
|
SUTENT |
123 |
|
TALNETANT |
124 |
|
BL-1030 |
124 |
|
BL-1050 |
124 |
|
Table 57 GASTROINTESTINAL DISORDER TREATMENTS IN DEVELOPMENT |
124 |
|
Table 57 (CONTINUED) |
125 |
|
Table 57 (CONTINUED) |
126 |
|
Table 57 (CONTINUED) |
127 |
|
INDUSTRY PARTICIPANTS BY PRODUCT TYPE |
128 |
|
Table 58 GASTROINTESTINAL DISORDER TREATMENT MANUFACTURERS BY TYPE, 2004 |
128 |
|
COMPANY PROFILES |
129 |
|
ASTRAZENECA |
129 |
|
History |
129 |
|
AXCAN PHARMA INC. |
130 |
|
History |
130 |
|
CENTOCOR INC |
131 |
|
History |
131 |
|
EISAI INC |
132 |
|
History |
132 |
|
GENENTECH INC. |
132 |
|
History |
133 |
|
GLAXOSMITHKLINE |
133 |
|
GlaxoSmithKline (Continued) |
134 |
|
GlaxoSmithKline (Continued) |
135 |
|
History |
136 |
|
JOHNSON & JOHNSON |
136 |
|
History |
137 |
|
MCNEIL CONSUMER HEALTHCARE |
137 |
|
History |
137 |
|
MERCK & COMPANY INC. |
138 |
|
History |
138 |
|
NOVARTIS INTERNATIONAL AG |
139 |
|
History |
139 |
|
PFIZER INC. |
140 |
|
History |
140 |
|
PROCTER & GAMBLE COMPANY |
141 |
|
History |
141 |
|
ROCHE |
142 |
|
History |
142 |
|
SANOFI-AVENTIS |
142 |
|
History |
143 |
|
SOLVAY PHARMACEUTICALS |
143 |
|
History |
144 |
|
TAP PHARMACEUTICALS PRODUCTS INC. |
144 |
|
History |
144 |
|
WYETH |
145 |
|
History |
146 |
|
APPENDIX |
147 |
|
COMPANY DIRECTORY |
147 |
|
3M CORPORATION |
147 |
|
ABBOTT LABORATORIES |
147 |
|
ACAMBIS PLC |
147 |
|
ADERIS PHARMACEUTICALS (DISCOVERY THERAPEUTICS) |
147 |
|
ADOLOR CORPORATION |
147 |
|
ALIZYME PLC |
148 |
|
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. |
148 |
|
ALTANA PHARMA AG |
148 |
|
AMARIN CORPORATION |
148 |
|
APOTHECON B.V. |
148 |
|
ARCO PHARMACEUTICALS |
149 |
|
ASTRAZENECA PLC |
149 |
|
AXCAN PHARMA INC. |
149 |
|
BERLEX LABORATORIES INC. |
149 |
|
BERTEK (MYLAN LABORATORIES INC.) |
149 |
|
BIOGEN IDEC INC. |
149 |
|
BIOLINERX LTD. |
150 |
|
BIOPORT CORPORATION |
150 |
|
BRAINTREE LABORATORIES INC. |
150 |
|
BRISTOL-MYERS SQUIBB COMPANY |
150 |
|
CENTOCOR, INC |
150 |
|
CHEMOCENTRYX INC. |
150 |
|
CYTOKINE PHARMASCIENCES INC. |
151 |
|
DOR BIOPHARMA INC. |
151 |
|
EISAI CO., LTD. |
151 |
|
ELAN CORPORATION PLC |
151 |
|
ELKINS-SINN INC. |
151 |
|
FIRST HORIZON CORPORATION |
151 |
|
GENAERA CORPORATION |
152 |
|
GENENTECH INC. |
152 |
|
GENZYME GENERAL |
152 |
|
GLAXOSMITHKLINE PLC |
152 |
|
GLAXOSMITHKLINE CONSUMER HEALTHCARE |
152 |
|
HOFFMAN-LAROCHE LTD. (ROCHE) |
152 |
|
IMMUCELL CORPORATION |
153 |
|
INKINE PHARMACEUTICAL COMPANY INC. |
153 |
|
ISIS PHARMACEUTICALS INC. |
153 |
|
IVAX CORPORATION |
153 |
|
JANSSEN PHARMACEUTICA PRODUCTS L.P. (JOHNSON & JOHNSON) |
153 |
|
CMS, P&A House, Alma Road, Chesham, Bucks. HP5 3HB, UK Tel: +44 (0)1494 771734 Fax: +44 (0)1494 778994 e-mail: jenniferc@cmsinfo.com copyright © 2005 all rights reserved For more information about us, visit CMSinfo.
 |
